Brought to you by 
Qiagen buys DxS for $95mm plus earn-outs
Oct 2009
Executive Summary
Qiagen NV (samples and assays for disease prevention, profiling, and personalized medicine) has acquired privately held UK molecular diagnostics firm DxS for $95mm, plus up to $35mm more in potential earn-outs.
Deal Industry
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
- Pharmaceuticals
-
Research, Analytical Equipment & Supplies
- PCR & Amplification Tools
Deal Status
- Final
Deal Type
-
Acquisition
- Includes Earnout
- Intra-Biotech Deal
- Full Acquisition
- Acquisition of Private Biotech
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com